Prominent Accumulation in Hemodialysis Patients of Solutes Normally Cleared by Tubular Secretion

Overview

Journal J Am Soc Nephrol

Specialty Nephrology

Date 2013 Nov 16

PMID 24231664

Citations 68

Authors

Tammy L Sirich

Benjamin A Funk

Natalie S Plummer

Thomas H Hostetter

Timothy W Meyer

Affiliations

Soon will be listed here.

Abstract

Dialytic clearance of urea is efficient, but other small solutes normally secreted by the kidney may be cleared less efficiently. This study tested whether the high concentrations of these solutes in hemodialysis patients reflect a failure of passive diffusion methods to duplicate the efficacy of clearance by tubular secretion. We compared the plasma concentrations and clearance rates of four solutes normally cleared by tubular secretion with the plasma concentrations and clearance rates of urea and creatinine in patients receiving maintenance hemodialysis and normal subjects. The predialysis concentrations (relative to normal subjects) of unbound phenylacetylglutamine (122-fold), hippurate (108-fold), indoxyl sulfate (116-fold), and p-cresol sulfate (41-fold) were much greater than the concentrations of urea (5-fold) and creatinine (13-fold). The dialytic clearance rates (relative to normal subjects) of unbound phenylacetylglutamine (0.37-fold), hippurate (0.16-fold), indoxyl sulfate (0.21-fold), and p-cresol sulfate (0.39-fold) were much lower than the rates of urea (4.2-fold) and creatinine (1.3-fold). Mathematical modeling showed that prominent accumulation of the normally secreted solutes in hemodialysis patients could be accounted for by lower dialytic clearance relative to physiologic clearance combined with the intermittency of treatment. Whether or not more efficient removal of normally secreted solutes improves outcomes in dialysis patients remains to be tested.

Citing Articles

Depletion by Hemodialysis of the Antioxidant Ergothioneine.

Suba J, Keo L, Sirich T Kidney360. 2025; 6(2):265-271.

PMID: 39869777 PMC: 11882260. DOI: 10.34067/KID.0000000645.

Gut microbiota and their metabolites in hemodialysis patients.

Du J, Zhao X, Ding X, Ren Q, Wang H, Han Q Chin Med J (Engl). 2025; 138(4):502-504.

PMID: 39809700 PMC: 11845176. DOI: 10.1097/CM9.0000000000003423.

Analysis of Levels of Vitamin D, Beta-Amyloid 42, Indoxyl Sulfate, and Serum Parathyroid Hormone in Hemodialysis Patients with Cognitive Impairment.

Syafrita Y, Harun H, Susanti R, Indra S Innov Clin Neurosci. 2025; 21(10):44-47.

PMID: 39790902 PMC: 11709437.

The Role of the Gut Microbiota in Complications among Hemodialysis Patients.

Du J, Zhao X, Ding X, Han Q, Duan Y, Ren Q Microorganisms. 2024; 12(9).

PMID: 39338552 PMC: 11434415. DOI: 10.3390/microorganisms12091878.

Using established biorepositories for emerging research questions: a feasibility study.

Lerink L, Sutton C, Otten H, Faro L, Ploeg R, Lindeman J Clin Proteomics. 2024; 21(1):54.

PMID: 39154002 PMC: 11330044. DOI: 10.1186/s12014-024-09504-6.

References

Meijers B, de Loor H, Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P . p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clin J Am Soc Nephrol. 2009; 4(12):1932-8. PMC: 2798868. DOI: 10.2215/CJN.02940509. View

Burckhardt G . Drug transport by Organic Anion Transporters (OATs). Pharmacol Ther. 2012; 136(1):106-30. DOI: 10.1016/j.pharmthera.2012.07.010. View

Vanholder R, Meert N, Van Biesen W, Meyer T, Hostetter T, Dhondt A . Why do patients on peritoneal dialysis have low blood levels of protein-bound solutes?. Nat Clin Pract Nephrol. 2008; 5(3):130-1. DOI: 10.1038/ncpneph1023. View

Eloot S, Torremans A, De Smet R, Marescau B, De Deyn P, Verdonck P . Complex compartmental behavior of small water-soluble uremic retention solutes: evaluation by direct measurements in plasma and erythrocytes. Am J Kidney Dis. 2007; 50(2):279-88. DOI: 10.1053/j.ajkd.2007.05.009. View

Meyer T, Leeper E, Bartlett D, Depner T, Lit Y, Robertson C . Increasing dialysate flow and dialyzer mass transfer area coefficient to increase the clearance of protein-bound solutes. J Am Soc Nephrol. 2004; 15(7):1927-35. DOI: 10.1097/01.asn.0000131521.62256.f0. View

GULYASSY P, Depner T . Impaired binding of drugs and endogenous ligands in renal diseases. Am J Kidney Dis. 1983; 2(6):578-601. DOI: 10.1016/s0272-6386(83)80038-9. View

Nigam S, Bush K, Bhatnagar V . Drug and toxicant handling by the OAT organic anion transporters in the kidney and other tissues. Nat Clin Pract Nephrol. 2007; 3(8):443-8. DOI: 10.1038/ncpneph0558. View

Itoh Y, Ezawa A, Kikuchi K, Tsuruta Y, Niwa T . Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem. 2012; 403(7):1841-50. DOI: 10.1007/s00216-012-5929-3. View

Sekine T, Miyazaki H, Endou H . Molecular physiology of renal organic anion transporters. Am J Physiol Renal Physiol. 2006; 290(2):F251-61. DOI: 10.1152/ajprenal.00439.2004. View

10.

Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R . Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012; 23(7):1258-70. PMC: 3380651. DOI: 10.1681/ASN.2011121175. View

11.

Eraly S, Vallon V, Vaughn D, Gangoiti J, Richter K, Nagle M . Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice. J Biol Chem. 2005; 281(8):5072-83. DOI: 10.1074/jbc.M508050200. View

12.

Bricker N, KLAHR S, LUBOWITZ H, Rieselbach R . RENAL FUNCTION IN CHRONIC RENAL DISEASE. Medicine (Baltimore). 1965; 44:263-88. DOI: 10.1097/00005792-196507000-00001. View

13.

Schepers E, Glorieux G, Vanholder R . The gut: the forgotten organ in uremia?. Blood Purif. 2010; 29(2):130-6. DOI: 10.1159/000245639. View

14.

Pham N, Recht N, Hostetter T, Meyer T . Removal of the protein-bound solutes indican and p-cresol sulfate by peritoneal dialysis. Clin J Am Soc Nephrol. 2007; 3(1):85-90. PMC: 2390983. DOI: 10.2215/CJN.02570607. View

15.

Sirich T, Luo F, Plummer N, Hostetter T, Meyer T . Selectively increasing the clearance of protein-bound uremic solutes. Nephrol Dial Transplant. 2012; 27(4):1574-9. PMC: 3315673. DOI: 10.1093/ndt/gfr691. View

16.

Rhee E, Souza A, Farrell L, Pollak M, Lewis G, Steele D . Metabolite profiling identifies markers of uremia. J Am Soc Nephrol. 2010; 21(6):1041-1051. PMC: 2900954. DOI: 10.1681/ASN.2009111132. View

17.

Niwa T . Organic acids and the uremic syndrome: protein metabolite hypothesis in the progression of chronic renal failure. Semin Nephrol. 1996; 16(3):167-82. View

18.

Poesen R, Meijers B, Evenepoel P . The colon: an overlooked site for therapeutics in dialysis patients. Semin Dial. 2013; 26(3):323-32. DOI: 10.1111/sdi.12082. View

19.

Lesaffer G, De Smet R, Lameire N, DHondt A, Duym P, Vanholder R . Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant. 1999; 15(1):50-7. DOI: 10.1093/ndt/15.1.50. View

20.

Liu X, Chen C, Hop C . Do we need to optimize plasma protein and tissue binding in drug discovery?. Curr Top Med Chem. 2011; 11(4):450-66. DOI: 10.2174/156802611794480918. View